Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and zithromax

erlotinib hydrochloride has been researched along with zithromax in 1 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(zithromax)		Trials
(zithromax)		Recent Studies (post-2010) (zithromax)
4,3537863,0336,9641,2633,790

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)zithromax (IC50)
30S ribosomal protein S6Escherichia coli K-120.3
30S ribosomal protein S7Escherichia coli K-120.3
50S ribosomal protein L15Escherichia coli K-120.3
50S ribosomal protein L10Escherichia coli K-120.3
50S ribosomal protein L11Escherichia coli K-120.3
50S ribosomal protein L7/L12Escherichia coli K-120.3
50S ribosomal protein L19Escherichia coli K-120.3
50S ribosomal protein L1Escherichia coli K-120.3
50S ribosomal protein L20Escherichia coli K-120.3
50S ribosomal protein L27Escherichia coli K-120.3
50S ribosomal protein L28Escherichia coli K-120.3
50S ribosomal protein L29Escherichia coli K-120.3
50S ribosomal protein L31Escherichia coli K-120.3
50S ribosomal protein L31 type BEscherichia coli K-120.3
50S ribosomal protein L32Escherichia coli K-120.3
50S ribosomal protein L33Escherichia coli K-120.3
50S ribosomal protein L34Escherichia coli K-120.3
50S ribosomal protein L35Escherichia coli K-120.3
50S ribosomal protein L36Escherichia coli K-120.3
30S ribosomal protein S10Escherichia coli K-120.3
30S ribosomal protein S11Escherichia coli K-120.3
30S ribosomal protein S12Escherichia coli K-120.3
30S ribosomal protein S13Escherichia coli K-120.3
30S ribosomal protein S16Escherichia coli K-120.3
30S ribosomal protein S18Escherichia coli K-120.3
30S ribosomal protein S19Escherichia coli K-120.3
30S ribosomal protein S20Escherichia coli K-120.3
30S ribosomal protein S2Escherichia coli K-120.3
30S ribosomal protein S3Escherichia coli K-120.3
30S ribosomal protein S4Escherichia coli K-120.3
30S ribosomal protein S5Escherichia coli K-120.3
30S ribosomal protein S8Escherichia coli K-120.3
30S ribosomal protein S9Escherichia coli K-120.3
50S ribosomal protein L13Escherichia coli K-120.3
50S ribosomal protein L14Escherichia coli K-120.3
50S ribosomal protein L16Escherichia coli K-120.3
50S ribosomal protein L23Escherichia coli K-120.3
30S ribosomal protein S15Escherichia coli K-120.3
50S ribosomal protein L17Escherichia coli K-120.3
50S ribosomal protein L21Escherichia coli K-120.3
50S ribosomal protein L30Escherichia coli K-120.3
50S ribosomal protein L6Escherichia coli K-120.3
30S ribosomal protein S14Escherichia coli K-120.3
30S ribosomal protein S17Escherichia coli K-120.3
30S ribosomal protein S1Escherichia coli K-120.3
50S ribosomal protein L18Escherichia coli K-120.3
50S ribosomal protein L2Escherichia coli K-120.3
50S ribosomal protein L3Escherichia coli K-120.3
50S ribosomal protein L24Escherichia coli K-120.3
50S ribosomal protein L4Escherichia coli K-120.3
50S ribosomal protein L22Escherichia coli K-120.3
50S ribosomal protein L5Escherichia coli K-120.3
30S ribosomal protein S21Escherichia coli K-120.3
50S ribosomal protein L25Escherichia coli K-120.3
50S ribosomal protein L36 2Escherichia coli K-120.3

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and zithromax

ArticleYear
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
    Dermatology (Basel, Switzerland), 2012, Volume: 224, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors

2012